ALSO NOTED: Merck's Cordaptive fails to get U.S. approval; Medtronic sub faces FDA-imposed outage;

> In a blow to Merck's 2008 plans, the cholesterol candidate Cordaptive failed to get the FDA's OK; in a "not approvable letter," the agency asked for more data. Release

> The FDA has imposed new requirements on Medtronic's Physio-Control subsidiary after finding new manufacturing problems affecting its external defibrillators; the company faces an extended outage as it fixes the problems. Report

> Five officials from a Chinese pharma were sentenced to prison time for selling a tainted antibiotic that killed 13 people in 2006. Report

> Britain's consumer watchdog has asked GlaxoSmithKline--along with a host of big  brand-name companies--for pricing information as part of a price-fixing probe. Report

> As more drug marketing migrates online, pharma companies are struggling to determine their ROI on Internet promos. Report

> The Clinton Foundation and international drug-purchasing consortium Unitaid have struck deals for deeper discounts on more than 40 generic AIDS meds. Report

> The Indian government is mulling plans to cap retail drug margins and penalize drug makers that give pharmacists higher-than-allowed mark-ups. Report

> Pfizer plans to launch its stop-smoking drug Champix in Japan on May 8. Release

> Merck's Indian subsidiary launched its diabetes treatment Januvia in the subcontinent at a price comparable to other diabetes drugs. Report

> Teva got the FDA nod for its generic version of GlaxoSmithKline's Flolan, an IV drug for hypertension. Report'

> In what may signal a major shift in FDA standards, Isis and Genzyme say that they expect to add another year to the development timeline for a closely watched cholesterol therapy in order to produce data demonstrating a reduced risk of heart attacks and related diseases rather than just an ability to lower levels of cholesterol. Report

> Economic development officials in Baltimore are fretting that they're one step behind the pace being set in Montgomery County, where low-cost lab space along with offers of small loans and grants have been luring away emerging drug developers. Report

> Shares of Medarex slipped seven percent this morning as investors digested Friday's announcement that its application for a new cancer drug will be delayed into 2009. Medarex report

And Finally... Feeling thick-headed? Train your brain to be more intelligent. Report 

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.